<DOC>
	<DOCNO>NCT00413309</DOCNO>
	<brief_summary>To determine rate symptomatic asymptomatic gastrointestinal erosion ulceration patient dual antiplatelet ( aspirin clopidogrel ) therapy percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Gastrointestinal Ulceration Patients Dual Antiplatelet Therapy After Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Background Significance : Percutaneous coronary intervention ( PCI ) standard care patient acute coronary syndrome ( ACS ) . Approximately 1,200,000 PCIs perform 2002 United States . Drug-eluting coronary stent nearly abolish clinical problem in-stent restenosis cost increase susceptibility in-stent thrombosis , catastrophic event associate 6-month mortality rate 8.9 % myocardial infarction rate exceed 50 % . To prevent in-stent thrombosis , PCI patient receive aspirin 325 mg minimum load dose clopidogrel 300 mg prior stent deployment . In actual practice , many patient receive clopidogrel load dose 600 mg ensure adequate platelet inhibition . Muller et al show administration higher load dose ( 600mg ) clopidogrel patient undergo PCI accelerate suppression platelet aggregation evaluate aggregometry . When patient give high load dose ( 600mg ) clopidogrel oppose conventional loading dose ( 300mg ) , 50 % reduction myocardial infarction PCI patient receive high dose . If 600 mg load dose clopidogrel adopt routine practice , may increase risk major gastrointestinal ( GI ) ulceration . In multivariable analysis , strong predictor stent thrombosis premature discontinuation dual antiplatelet therapy , exceed independent predictor renal failure , bifurcation lesion , diabetes , low ejection fraction . Hence , follow PCI drug-eluting stent , dual antiplatelet therapy , aspirin 75 162 mg lifelong combination clopidogrel 75 mg least 3 month , prescribe . The risk overt GI bleed dual antiplatelet therapy high 1.3 % within first 30 day therapy . Weil et al find dos aspirin associate increase risk GI bleeding risk GI bleed due low-dose aspirin dose-related : odds ratio 2.3 75 mg ⁄day ; 3.2 150 mg ⁄day ; 3.9 300 mg ⁄day . In Clopidogrel Unstable angina prevent Recurrent Events ( CURE ) study , Peters et al show risk bleed high dose aspirin ( ≥ 200mg ) give placebo high ( 3.7 % ) risk GI bleed combination clopidogrel aspirin low dose group ( 3.0 % ) . Kelly et al show relative risk upper GI bleeding plain , enteric-coated , buffer aspirin average daily dose 325 mg less 2.6 , 2.7 , 3.1 , respectively . Conventional thinking compare stomach , relatively alkaline duodenum less susceptible aspirin-induced damage . However , Kelly et al find contrast conventional think relative risk point estimate three form aspirin approximately gastric duodenal bleeding . A possible explanation systemic effect ( e.g. , platelet prostaglandin synthesis ) unlikely differ accord aspirin preparation use may overwhelm difference local effect gastric duodenal mucosa . In addition local irritation gastric mucosa , aspirin antiplatelet agent cause gastric damage inhibition prostaglandin synthesis produce microcirculatory injury . Antiplatelet drug might interfere gastric ulcer heal suppress release growth factor , vascular endothelial growth factor ( VEGF ) , platelet . Patients high risk GI bleed antiplatelet therapy elderly , patient history gastric ulcer , gastroesophageal reflux disease ( GERD ) , esophagitis , untreated Helicobacter pylorus infection , intestinal polyp , cancer , concomitant use anticoagulant , steroid , nonsteroidal anti-inflammatory drug ( NSAIDS ) . Patients dual antiplatelet therapy develop upper low GI bleeding . GI hemorrhage associate increased mortality rate , great need surgery , blood transfusion , prolong length hospital stay , increase overall health care cost . While upper GI bleeding prevent appropriate prophylaxis , prophylaxis low GI bleeding . Acid-suppressive therapy beneficial prevention upper GI bleed . Two major class agent prevention upper GI bleeding due ulcer complication antiplatelet therapy : 1 ) acid-suppressive therapy H2-antagonists 2 ) proton pump inhibitor ( PPIs ) . H2-antagonists exert therapeutic effect reversibly block H2-receptors basolateral membrane gastric parietal cell . Until early 1990s , H2-antagonists mainstay pharmacotherapy prevention management upper GI bleeding . Between 1984 2000 , 32 randomize control trial conduct compare H2-antagonists placebo . Agents evaluated study include cimetidine , ranitidine , famotidine . Many limit small sample size wide variation study design . In meta analysis 11 randomize control trial H2-antagonists , Koch et al show H2-antagonists prevent gastric ulcer , either short-term ( &lt; 2weeks ) long-term ( &gt; 4weeks ) NSAID treatment . The average baseline risk gastric ulcer find 3.6 % 6.8 % short- long-term NSAID treatment , respectively . The average baseline risk gastric lesion 53 % 27 % short- long-term NSAID treatment , respectively . The H2 blocker lead significant risk reduction gastric lesion either short-term long-term therapy . A statistical advantage H2 blocker show 1 9 study . The average baseline risk duodenal ulcer find 3 % 4 % short- long-term NSAID treatment , respectively . The H2 blocker lead significant reduction risk duodenal ulcer short-term treatment . A statistical advantage H2 blocker show 3 5 long-term study , none 4 short-term trial . The average baseline risk duodenal lesion find 11 % 12 % short- long-term NSAID treatment , respectively . The H2 blocker lead significant reduction risk duodenal lesion , either short-term long-term treatment . Factors limit utility H2-antagonists include development tachyphylaxis , need dosage adjustment renal insufficiency , thrombocytopenia , mental status change see high dos medication . With introduction safer effective agent like PPIs , role H2-antagonists prevention management upper GI bleeding diminish . PPIs work irreversibly inhibit H+ pump gastric parietal cell . PPIs number theoretical advantage H2-antagonists . First , PPIs block final step acid production , negate stimulation gastric secretion gastrin , histamine , acetylcholine , lead prolonged acid suppression . Second , unlike H2-antagonists , tachyphylaxis note PPIs . Yeomans et al show omeprazole ( PPIs ) effective H2 receptor antagonist gastric acid suppression , prevent ulcer , heal ulcer related chronic use NSAIDS . In randomized , open-label , five-way crossover study , 24-h intragastric pH profile oral esomeprazole 40 mg , lansoprazole 30 mg , omeprazole 20 mg , pantoprazole 40 mg , rabeprazole 20 mg daily 34 patient symptoms gastroesophageal reflux disease evaluate . Intragastric pH maintain 4.0 mean 14.0 h esomeprazole , 12.1 h rabeprazole , 11.8 h omeprazole , 11.5 h lansoprazole , 10.1 h pantoprazole . Esomeprazole also provide significantly high percentage patient intragastric pH great 4.0 12 h relative proton pump inhibitor . The frequency adverse event similar among treatment group . Esomeprazole standard dose 40 mg daily provide effective control gastric acid steady state standard dose PPIs . Chan et al randomize 320 patient previous bleed aspirin clopidogrel placebo versus aspirin esomeprazole . The cumulative incidence ulcer bleed study 8.6 % patient receive clopidogrel 0.7 % patient receive aspirin esomeprazole . Esomeprazole 40 mg day find efficacious esomeprazole 20 mg day 10 mg day heal erosive esophagitis gastritis without significant difference long-term safety tolerability . Esomeprazole extensively metabolize liver CYP3A4 clinically relevant interaction drug metabolize CYP system report . Assessment GI Ulceration : To detect GI ulceration , endoscopy `` gold standard '' . However , invasiveness traditional endoscopy PCI patient coronary artery disease make approach inappropriate . An alternative imaging test noninvasive require sedation PillCamÒ ESO capsule endoscope . The disposable , ingestible PillCamÒESO endoscope 11 X 26 mm capsule acquire video image end device passage esophagus . The capsule transmits acquire image via digital radiofrequency communication channel data recorder unit locate outside body . The data recorder , external receiving/recording unit worn patient 's belt . It receive data transmit capsule . Upon completion examination , physician transfer accumulate data data recorder transfer computer software process interpretation . The sensitivity PillCamÒ ESO diagnose esophageal abnormality 92 % negative predictive value ( NPV ) 88 % . Specificity positive predictive value diagnose esophageal abnormality ( PPV ) 95 % 97 % , respectively . The PillCamÒ ESO capsule intend visualization esophagus stomach adult patient , detection gastritis feasible . The PillCamÒ ESO capsule contraindicate use follow condition : - Known suspected GI obstruction , stricture , fistula base clinical picture pre-procedure test profile . - Cardiac pacemaker implant electromedical device . - Swallowing disorder . In investigator-initiated trial , enroll 30 patient require dual antiplatelet therapy PCI determine rate occult overt GI ulceration patient antiplatelet therapy PCI . All patient receive PillCamÒ ESO endoscopy 80-90 day aspirin clopidogrel therapy detect gastric erosion ulcer . This provide u event rate GI ulceration patient dual antiplatelet therapy without acid suppressive medication prophylaxis .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>1 . Patients undergone PCI within precede 72 hrs 2 . Patients aspirin clopidogrel 3 . Age great 18 year less 80 year 4 . Written inform consent 1 . Active bleed 2 . Pregnancy 3 . Patients already H2 antagonists 4 . Patients already PPI 5 . Patients implanted cardiac defibrillator ( ICD ) 6 . Patients GI stricture , swallow disorder , bowel obstruction fistula . 7 . Patients significant gastrointestinal diverticular disease 8 . Patients likely require MRI imaging time PillCam still digestive tract ( 8 72 hour PillCam procedure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Antiplatelet Therapy</keyword>
	<keyword>PillCam</keyword>
	<keyword>Endoscopy</keyword>
</DOC>